The extent of co-expression of estrogen receptors (ER) and progesterone receptors (PgR) in breast cancer cells was examined immunocytochemically. Eight surgical cases of infiltrating ductal carcinoma designated as ER-positive and PgR-positive (ER+ /PgR+) by enzyme i"un0assay (EM) were used. They were fixed with 4% formaldehyde and cut into serial frozen semithin sections. Using sections stained with either anti-ER or anti-PgR antibody, we ascertained the co-localization of ER and PgR in a single cell and estimated the ratio of the number of cells m-exptessing ER and PgR. Twenty-Six to 95% of the cells were immunopositive for both ER and PgR, 2-25% of them, varying in cases, were positive for ER but not for PgR, and <3% of the cells were positive for PgR but not for ER. The remaining 5-60% cells were
Introduction
Estradiol and progesterone have important roles in development and differentiation of mammary gland tissues and proliferation of breast cancer tissues (King, 1993) . Their effects are mediated by the estrogen receptors (ER) and the progesterone receptors (PgR) in the target cells. These receptors are located in cell nuclei (King and Greene, 1984; Welshons et al., 1984) , and they modify transcriptional activity of genes as do other members of the steroid hormone receptor family (Baniahmad and %ai, 1993) . In breast cancer, biochemical measurements, including enzyme immunoassay (EIA), of ER and PgR have been applied to breast cancer tissues. These hormone receptors have been regarded as important parameters for assessment of the hormone sensitivity of breast cancer tissues (Pichon et al., 1992; Knight et al., 1977) . ER presence of ER and PgR has been reported to be heterogeneous among cells within a tissue, and the ratio of the population of cells showing immunoreactivity for ER or PgR in breast cancer varies among cases (Fukushima et al., 1995; Press and Greene, 1988; King et al., 1985) . Previous investigators quantified the percentage of ERor PgR-positive cells and their immunoreactive intensity by immunocytochemical assay (ICA), and showed a correlation between the ICA value and the hormone sensitivity of tumors (Allred et al., 1990) .
Although previous immunohistochemical studies showed that cells in breast cancer tissues have subpopulations with ER or PgR, they were not concerned with the correlation of the population of ER-immunoreactive cells with PgR-immunoreactive cells at the cellular level. Therefore, we decided to examine the extent of the colocalization of ER and PgR in cells in breast cancer tissues. Because monoclonal anti-ER and -PgR antibodies that have been widely used for EIA and ICA of ER and PgR for the assessment of surgical specimens were raised in the same species (rat), double staining of single sections is often difficult to exclude the crossreaction of anti-rat immunoglobulin of the secondary antibodies. Therefore, we used frozen semithin sections of surgical cases of breast cancer and cut serial 1-pm-thick sections. Adjacent semithin sections were alternatively immunostained with anti-ER or anti-PgR to compare the ER and PgR immunoreactivity of cells, as the nucleus of a single cell is expected to be divided into a t least two sections.
Materials and Methods
Monoclonal antibodies (MAbs) for rat anti-human ER, H222 (Greene et al., 1980) and rat anti-human PgR, KD68 . obtained from Abbott Laboratories (Chicago, IL). were used in the present study. These MAbs have been applied to clinical detection of ER or PgR of breast cancer specimens, i.e., in EIA and ICA.
Eight randomly chosen surgical specimens of infiltrating ductal breast cancer were used, which were collected in the Department of Surgery, Kyorin University Hospital, between April of 1994 and December of 1994. These were classified as ER-positive and PgR-positive (ER+ /PgR+ ) breast cancer by EIA. Each specimen was sliced into several portions with razor blades and was processed for routine histological examination, EIA for tissue content of ER and PgR (Fukushima et al., 1995) , or immunocytochemistry using semithin and ultrathin frozen sections.
For semithin and ultrathin cryosections, portions of sliced tissues were cut into small pieces, rapidly immersed in 4% formaldehyde in 0.1 M phosphate-buffer (PB), pH 7.4, incubated at 4'C for 1 hr, briefly rinsed with cold PBS, and immersed in 2.3 M sucrose-PB at 4'C for 1 hr. Our preliminary experiments had confirmed that the 1-hr fixation employed in the present study provided better preservation of cellular structures and that longer prefxation caused markedly weaker immunostaining. The tissue pieces were then rapidly frozen with liquid nitrogen and stored at -8O'C until sectioning was done. Cryosectioning was performed as previously described (Takata and Hirano, 1990) . Frozen sections were cut with a Sorvall MT-2B ultramicrotome equipped with a CR21 cryosectioning attachment (RMC; Tucson, AZ).
Semithin sections about 1 pm thick were mounted on neoprene-coated glass slides, washed with PBS, and treated with 1% bovine serum albumin (BSA, fraction V; Sigma, St Louis, MO)-PBS for 15 min. Each of the adjacent sections was then alternatively incubated with rat anti-human ER or PgR antibody (ERand PgR-ICA kits, Abbott) for 1 hr at room temperature, washed with PBS, and subsequently incubated with 1.2 pglml donkey anti-rat IgG-Cy3 (indocarbocyanine; Jackson Immunoresearch, West Grove, PA). DAPI (4',6-diamidino-2-phenylndole.2HC1; Boehringer. Mannheim, Germany) was added to the secondary antibody solution for counterstaining of nuclei. After washing with PBS. the specimens were mounted with buffered glycerol and observed with a Nikon microscope equipped with an epifluorescence system and Nomarski differential interference optics.
Ultrathin sections were immunostained with anti-ER or anti-PgR ('Gkata and Hirano. 1990 ). Goat anti-rat IgG (Zymed; San Francisco, CA) conjugated with colloidal gold particles (12 nm) was used as the secondary antibody. At both light and electron microscopic levels, as immunocytochemical control experiments, normal rat IgG supplied in the ICA kits (Abbott) as the control antibody was used instead of anti-ER or -PgR antibody.
For comparison of serial sections that were immunostained for ER or PgR, photomicrographs of immunofluorescence, DAPI counterstaining, and Nomarski image of each semithin section were introduced to a Macintosh computer by a film scanner (Nikon LS-10). Image processing was performed by use of the public domain NIH Image program (developed at the National Institutes of Health) for identification of immunoreactive signals for the presence of ER or PgR. Filters for "noise reduction" and "background subtraction," available on the program, were used. Figure 1 shows an example of this image enhancing process. The area of each nucleus used for the comparison consisted of200-400 pixels. Cy3 staining intensity was q r e s e d as the average optical density of the pixels in a DAPI-labeled nuclev area. The average optical density of each nucleus was compared with that in the cytochemical control by Welch's t-test. Cells whose staining intensity showed significant differences (p < 0.05) from the background level were considered positive for ER or PgR. When the nucleus was intensely stained with Cy3. it was considered as positively immunoreactive without the statistical comparison. In all pairs of optical fields from serial sections used for cell counting, over 95 % of the nuclei were confirmed to be from identical cells by matching the topographical localization of the DAPI image and the Nomarski image of the pairs of sections. For each breast cancer tissue from a given patient, at least 300 cells from three to five randomly chosen small tissue blocks were used to estimate the co-localization ratio of ER and PgR. (Figure 4) , nuclei of almost all the cells in the twoadjacent sectionsshowed co-localization of ER with PgR (arrows). In case No. 6 ( Figure 5) . most nuclei of the cells in a were labeled with anti-ER, but in an adjacent section (b) some of these flUClei were not labeled with anti-PgR (arrowheads). In this case, the population of cells co-localizing ER with PgR was relatively small. Original magnification x 125. Bars = 5 Fm. Figure 2 shows immunofluorescence labeling for ER in a semithin section of breast cancer tissue at a high magnification. Cy3-labeled signals were distributed in nuclei of cancer cells. In particular, the nucleoli and the marginal area of the nuclei were essentially negative with either of the two MAbs. Cytoplasm and extracellular materials also were not stained. Immunocytochemical control sections showed no labeling in these tissues (data not shown). The staining pattern for anti-PgR immunocytochemistry was essentially identical to that for anti-ER.
Results

Localization of Immunoreactive ER and PgR
At the electron microscopic level, colloidal gold particles representing ER or PgR were found exclusively in the nucleus of the cancer cells (Figures 3a and 3b) . They were primarily located in euchromatin and condensed chromatin, and labels in nuclear membrane-associated and nucleolus-associated condensed chromatin were less frequently found than in euchromatin. In the nucleolus, few gold particles were found. In both the ER and the PgR reaction, a small number ofparticles were scattered in the cytoplasm. Signals in the cytoplasm were not observed in any particular organelles. Cytochemical controls showed essentially negative labeling for ER and PgR (Figure 3c ).
CO-localization of ER-and PgR-immunoreactive Cells in Breast Cancer Tissue
Figures 4 and 5 are photomicrographs of adjacent semithin sections of cancer tissues from different patients. In Figure 4 , almost all cells were labeled with both anti-ER and -PgR. In Figure 5 , however, most cells were labeled with anti-ER, but some of these cells were not labeled with anti-PgR. ER and PgR were co-localized in a cell in a certain population of cells in all of the cases thus far assessed in the present study.
As shown in Figure 6 , ER and PgR were co-expressed in 26-90% of the total cells. In cancer tissues from all the patients, cells coexpressing both ER and PgR were much more numerous than those expressing only one hormone receptor. The ratio of cells expressing only ER to total cells varied among the cases (2-25%). On the other hand, cells expressing only PgR were always very few (<3%). The remaining cells, expressing none of these hormone receptors, were 5-60% of total cells.
Discussion
We demonstrated here the co-localization of ER and PgR in a single breast cancer cell and the presence of a population of ER-positive but PgR-negative cells in biochemically ER+ lPgR + breast cancer tissues. We also quantified the ratio of each cell type by comparison of serial semithin frozen sections of the tumors.
In the present study, ER and PgR were immunocytochemically detected in the nuclei of cancer cells. The results showing that ER was distributed mainly in the euchromatin of the nuclei, but not in the nucleoli, are consistent with our previous observation made by the preembedding staining method (Fukushima et al., 1995) and with the results of another group (Press et al., 1985) . The localization of ER is also consistent with recent results of immunocytochemistry using ultrathin cryosections from mouse uterus (Yamashita, 1995) and of a study examining estrogen analogue binding to living cells (Miksicek et al., 1995) .
By comparison of one semithin section stained for ER with the adjacent serial section stained for PgR, we demonstrated that ER was often located in the same nucleus containing PgR. Moreover, the majority of ER-positive cells were also positive for PgR in all breast cancer specimens assessed ( Figure 6 ) that were biochemically ER+ /PgR+ . In breast cancer cell lines, expression of PgR is upregulated by estradiol, whose effect is mediated by ER (Nardulli PgR-) to total cells in ductal breaSt cancer tissues from eight patients. Read et al., 1988) . Therefore, it is reasonable to expect that the expression of PgR in breast cancer tissues correlates with that of ER. The present study showed evidence for this at the cellular level. However, the ratio of colocalization varied among cases, as shown in Figure 6 . In the case having the highest co-localization ratio (No. 1). more than 95% of the ER-positive cells were simultaneously positive for PgR. In contrast, in the other cases the co-localization ratio was lower. For example, only ~6 0 % of the ER-positive cells were also positive for PgR in patient No. 6. Concerning the present cases, a considerable percentage (2-25 % of total cancer cells assessed) of ER-positive but PgR-negative cells was present in most cases. In contrast, ER-negative and PgR-positive cells were always fewer (<3% of total cancer cells assessed). Because the cell cycle-dependent expression of ER has been reported to occur in a partially synchronized human breast cancer cell line, MCF7 (Dong et al., 1991; Jakesz et al., 1984) , the cell cycle phase of breast cancer cells might be related to the heterogeneity in receptor content or the responsiveness to hormones. In the present study, other regulatory mechanisms of expression of ER and PgR may be involved in the heterogeneity of expression of ER and PgR in breast cancer. Because the ratio of the cells expressing only ER varied among the cases and cells expressing only PgR were always few, we suggest that the expression of ER and PgR is differentially controlled and that the loss of ER precedes that of PgR.
However, it is still unclear whether or not this different expression pattern of ER and PgR stems from a genetic damage to cells. On the other hand, some breast cancer cases are regarded as being biochemically ER+ IPgRor ER-/PgR+ owing to a genetic disorder of receptor genes or of the regulatory mechanism of receptor expression in cancer tissues (Sluyser, 1992) . These cases are different in sensitivity to hormonal therapy and subsequent prognosis compared with ER+lPgR+ breast cancers (Pichon et al., 1992; Knight et al., 1977) . Cappelletti et al. (1991) co-cultured two breast cancer-derived cell lines, one ER-positive and the other ER-negative and showed complicated proliferative profiles of the co-culture under conditions with or without estrogen. In ER+ /PgR+ breast cancers, the role of ER-positive and PgR-negative cells in the hormone responsiveness of whole cancer tissues must be proved.
In conclusion, immunolabeling of serial semithin frozen sections for two or more markers is a useful method to assess the correlation of localization of dlfferent kinds of antigens, especially when the antisera used were raised in the same species. By using the same antibodies widely applied for EIA and ICA, a technical base for comparison of the present parameters with EIA and ICA data was established in the present study. The variety of the co-expression ratio of ER with PgR in biochemically ER+ /PgR+ breast cancer may reflect a certain clinical parameter, such as heterogeneous responsiveness of ER+ /PgR+ breast cancers to hormonal treatment.
